2020
DOI: 10.1016/j.intimp.2020.106549
|View full text |Cite
|
Sign up to set email alerts
|

Chronotherapy targeting cytokine secretion attenuates collagen-induced arthritis in mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
8
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(10 citation statements)
references
References 32 publications
0
8
0
1
Order By: Relevance
“…There is even evidence that leukocyte infiltration to tissues could exhibit its own rhythm (Scheiermann et al, 2013). Furthermore, mice with experimental arthritis showed a significantly decreased arthritis score when given baricitinib, a cytokine blocker, at ZT0 rather than ZT12 (Yaekura et al, 2020). This again highlights the temporal dependency of chronic pain at the behavioral and treatment level.…”
Section: Discussion and Future Directionsmentioning
confidence: 91%
“…There is even evidence that leukocyte infiltration to tissues could exhibit its own rhythm (Scheiermann et al, 2013). Furthermore, mice with experimental arthritis showed a significantly decreased arthritis score when given baricitinib, a cytokine blocker, at ZT0 rather than ZT12 (Yaekura et al, 2020). This again highlights the temporal dependency of chronic pain at the behavioral and treatment level.…”
Section: Discussion and Future Directionsmentioning
confidence: 91%
“…In collagen-induced arthritis mice models, the diurnal variation in the expression of inflammatory cytokines was observed. Subsequently, the superior effect of baricitinib was observed when the drug was administered in a period (evening) where the cytokine production was the highest (Yaekura et al, 2020). Similarly, diurnal variation of the pro-inflammatory cytokine, IL-6, has been observed in humans (Gudewill et al, 1992).…”
Section: Janus-associated Kinase Inhibitormentioning
confidence: 96%
“…Baricitinib is an oral JAK1/JAK2 inhibitor that has been shown to modulate innate and adaptive immune responses by inhibiting the production of inflammatory cytokines including TNF-α, IL-6, IL-17, and IFN-γ 100 and to profoundly reduce inflammation in animal models. 101 It is approved in over 65 countries for the treatment of rheumatoid arthritis. A small pilot study in 12 mild to moderate COVID-19 patients in Italy has suggested that baricitinib in combination with lopinavir/ritonavir may be safe for this study population and can improve clinical and laboratory parameters.…”
Section: Modulators Of Inflammation and Tissue Injurymentioning
confidence: 99%
“…Another class of anti-inflammatory agents that are being studied clinically are JAK inhibitors. Baricitinib is an oral JAK1/JAK2 inhibitor that has been shown to modulate innate and adaptive immune responses by inhibiting the production of inflammatory cytokines including TNF-α, IL-6, IL-17, and IFN-γ and to profoundly reduce inflammation in animal models . It is approved in over 65 countries for the treatment of rheumatoid arthritis.…”
Section: Modulators Of Inflammation and Tissue Injurymentioning
confidence: 99%